Omalizumab in the treatment of spontaneous chronic urticaria in SUS in the state of Bahia - synthesis of evidence on efficacy, safety and simplified estimate of budgetary impact

Published: 16 February 2023| Version 1 | DOI: 10.17632/r8trrrzkpm.1
Contributors:
Odailson Paz,

Description

To analyze and synthesize the available scientific research on the efficacy and safety of the treatment of patients with ECU, refractory antihistamines-H1, and to estimate the budgetary impact of their incorporation into SUS in Bahia. Methods: Synthesis of scientific tests, monitoring of simplified estimate of budgetary impact.

Files not available for this dataset

This contains only metadata

Categories

Therapeutic Procedure, Antibody, Urticaria, Efficacy Study

Licence